New York Life Investments ETF Trust NYLI U.S. Large Cap R&D Leaders ETF (LRND) seeks to track companies that demonstrate leadership in research and development spending within the large-cap U.S. equity universe. This strategy focuses on firms investing heavily in innovation and technological advancement to drive future growth.
How It Works
The ETF employs a rules-based methodology that screens large-cap U.S. companies based on their research and development expenditures as a percentage of revenue, selecting those with the highest R&D intensity. Holdings are weighted by market capitalization among qualifying companies that meet minimum R&D spending thresholds. The fund rebalances quarterly to maintain exposure to current R&D leaders and accommodate changes in company spending patterns.
Key Features
- Targets innovation-focused companies with high R&D spending, providing exposure to potential breakthrough technologies and patents
- Launched in October 2022, offering a relatively new approach to factor-based large-cap equity investing
- Zero expense ratio structure makes it cost-competitive for accessing R&D-focused investment strategy
Risks
- This ETF can lose value if R&D-intensive companies underperform, as high spending doesn't guarantee successful innovation or profitability
- Technology and healthcare sector concentration risk exists since these industries typically have the highest R&D expenditures
- As a newer fund with limited assets, liquidity constraints and tracking error risks may be higher than established ETFs
Who Should Own This
Best suited for growth-oriented investors with 3-5+ year time horizons seeking exposure to innovation-driven companies as a satellite holding (5-15% of equity allocation). Requires medium-to-high risk tolerance due to concentration in R&D-heavy sectors and the fund's recent inception with limited performance history.